← All protocols
NAD Precursor Supplementation
NAD+ precursors (NR, NMN) safely increase blood NAD+ levels by 40-200%, supporting mitochondrial function and metabolic health in aging adults.
NAD+ Decline
- 50% decline by age 50
- Impairs sirtuin activity
- Reduces DNA repair capacity
Supplement Effects
- NR/NMN increase NAD+: 40-200%
- Mitochondrial biogenesis enhanced
- Insulin sensitivity improved
Dosing
- NR: 100-500 mg/day, well-tolerated up to 2000 mg/day
- NMN: 250-500 mg/day
- Safety profiles: no serious adverse events in trials
Related registry entries
- NMN Supplementation (
nmn-supplementation) — NMN-focused dose ladders and safety wording. - NAD+ & Bioenergetics (
nad-bioenergetics) — exercise and lifestyle levers on NAD+ pools alongside precursors.
Tertiary map
Wikipedia: Nicotinamide adenine dinucleotide (wikipedia-nicotinamide-adenine-dinucleotide-overview) and Wikipedia: Nicotinamide mononucleotide (wikipedia-nicotinamide-mononucleotide-overview) give redox biochemistry and NMN product-class vocabulary—trial endpoints stay on linked PubMed rows here.
Evidence
- NAD+ metabolism and cellular aging
- Exercise and NAD+ metabolism in human muscle
- Wikipedia: Nicotinamide adenine dinucleotide
- Wikipedia: Nicotinamide mononucleotide
- A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
- Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
- Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans
- Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial